{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:30:08Z","timestamp":1794605408917,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"China Scientific Research Fund for HER2 Target from the China Anti-Cancer Association","award":["CORT-239-M14"],"award-info":[{"award-number":["CORT-239-M14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04643-z","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:36:23Z","timestamp":1769510183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study"],"prefix":"10.1186","volume":"24","author":[{"given":"Huimin","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongguo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"4785","key":"4643_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382.","journal-title":"Science"},{"issue":"5","key":"4643_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc1360","volume":"4","author":"A Gschwind","year":"2004","unstructured":"Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361\u201370.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4643_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim S-B, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519\u201330.","journal-title":"Lancet Oncol"},{"key":"4643_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast cancer. V.6.2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 03 Dec 2024."},{"key":"4643_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756.","journal-title":"Breast"},{"key":"4643_CR6","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-24-31","volume":"5","author":"J Li","year":"2024","unstructured":"Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, et al. Chinese society of clinical oncology (CSCO) breast cancer guidelines 2024. Translational Breast Cancer Research. 2024;5:18.","journal-title":"Translational Breast Cancer Research"},{"key":"4643_CR7","doi-asserted-by":"publisher","first-page":"17933","DOI":"10.1007\/s00432-023-05496-2","volume":"149","author":"S Hu","year":"2021","unstructured":"Hu S, Wu Y, Luan J, Wang S, Fan G. Cost\u2013utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting. J Cancer Res Clin Oncol. 2021;149:17933\u201342.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4643_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2022.10.010","volume":"66","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu K, Wang M, Wang K, Zhu H. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a cost-effectiveness analysis. Breast. 2022;66:191\u20138.","journal-title":"Breast"},{"key":"4643_CR9","doi-asserted-by":"publisher","first-page":"12078","DOI":"10.3389\/jpps.2023.12078","volume":"26","author":"K Gambaro","year":"2023","unstructured":"Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, et al. Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada. J Pharm Pharm Sci. 2023;26:12078.","journal-title":"J Pharm Pharm Sci"},{"issue":"29","key":"4643_CR10","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.19.00108","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib or lapatinib combined with capecitabine in her2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study. J Clin Oncol. 2019;37(29):2610\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4643_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351\u201360.","journal-title":"Lancet Oncol"},{"key":"4643_CR12","first-page":"1","volume":"30","author":"M Yan","year":"2020","unstructured":"Yan M, Bian L, Hu X, Zhang Q, Ouyang Q, Feng J, et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020;30:1\u201313.","journal-title":"Transl Breast Cancer Res"},{"issue":"3","key":"4643_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405\u201311.","journal-title":"Ann Oncol"},{"issue":"10265","key":"4643_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"3","key":"4643_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","volume":"20","author":"S Loi","year":"2019","unstructured":"Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial. Lancet Oncol. 2019;20(3):371\u201382.","journal-title":"Lancet Oncol"},{"key":"4643_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/tbcr-21-42","volume":"3","author":"T Wang","year":"2022","unstructured":"Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study. Transl Breast Cancer Res. 2022;3:15\u201325.","journal-title":"Transl Breast Cancer Res"},{"issue":"3","key":"4643_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305\u201314.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"4643_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.annonc.2020.10.600","volume":"32","author":"B Xu","year":"2021","unstructured":"Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Ann Oncol. 2021;32(2):218\u201328.","journal-title":"Ann Oncol"},{"issue":"6","key":"4643_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cct.2010.07.008","volume":"31","author":"AP Mander","year":"2010","unstructured":"Mander AP, Thompson SG. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemp Clin Trials. 2010;31(6):572\u20138.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"4643_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clbc.2015.06.002","volume":"15","author":"K Araki","year":"2015","unstructured":"Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, et al. Trastuzumab rechallenge after lapatinib- and trastuzumab-resistant disease progression in HER2-positive breast cancer. Clin Breast Cancer. 2015;15(6):432\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"4643_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdr474","volume":"23","author":"S Gori","year":"2012","unstructured":"Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol. 2012;23(6):1436\u201341.","journal-title":"Ann Oncol"},{"issue":"5","key":"4643_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00280-008-0682-1","volume":"62","author":"R Bartsch","year":"2008","unstructured":"Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, et al. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62(5):903\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4643_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"4643_CR24","unstructured":"CTCAE 5.0. Common Terminology criteria for adverse events (CTCAE). Version 5.0. Bethesda: National Cancer Institute; 2017."},{"issue":"7","key":"4643_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"4643_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21037\/atm-20-4054","volume":"9","author":"F Li","year":"2021","unstructured":"Li F, Xu F, Li J, Wang T, Bian L, Zhang S, et al. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. Annals Transl Med. 2021;9(2):103\u201310.","journal-title":"Annals Transl Med"},{"key":"4643_CR27","doi-asserted-by":"publisher","first-page":"682568","DOI":"10.3389\/fphar.2021.682568","volume":"12","author":"DJ Ouyang","year":"2021","unstructured":"Ouyang DJ, Chen QT, Anwar M, Xie N, Ouyang QC, Fan PZ, et al. The efficacy of pyrotinib as a third- or higher-line treatment in HER2-Positive metastatic breast cancer patients exposed to lapatinib compared to lapatinib-naive patients: a real-world study. Front Pharmacol. 2021;12:682568.","journal-title":"Front Pharmacol"},{"issue":"4","key":"4643_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im S-A, Cardoso F, Cort\u00e9s J, Curigliano G, Musolino A, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573\u201384.","journal-title":"JAMA Oncol"},{"key":"4643_CR29","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-22-35","volume":"3","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Ouyang Q, Li W, Chiu J, Yan M, Lu YS, et al. Efficacy and safety of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study. Translational Breast Cancer Research. 2022;3:31.","journal-title":"Translational Breast Cancer Research"},{"issue":"7","key":"4643_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, Kim S-B, Gonz\u00e1lez-Mart\u00edn A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689\u201399.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4643_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim S-B, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743\u201354.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4643_CR32","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30(8):2208\u201315.","journal-title":"Nat Med"},{"issue":"10","key":"4643_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283\u201395.","journal-title":"Lancet Oncol"},{"issue":"13","key":"4643_CR34","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial. Clin Cancer Res. 2022;28(13):2807\u201317.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4643_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","volume":"25","author":"L Fan","year":"2024","unstructured":"Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024;25(2):184\u201397.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4643_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(17)30088-8","volume":"18","author":"P Zhang","year":"2017","unstructured":"Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(3):371\u201383.","journal-title":"Lancet Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04643-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04643-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04643-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:15:20Z","timestamp":1771420520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04643-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4643"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04643-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP). The protocol was approved by the ethics committee of Henan Cancer Hospital (NO.2020\u2013341-003). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}